Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cenobamate: A Review in Focal-Onset Seizures.

CNS drugs·2025
Same author

Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.

CNS drugs·2024
Same author

Bimekizumab: A Review in Psoriatic Arthritis.

Drugs·2024
Same author

Correction: Eplontersen: First Approval.

Drugs·2024
Same author

Eplontersen: First Approval.

Drugs·2024
Same author

Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

Drugs·2023

相关实验视频

Updated: Jun 25, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

塔利卡巴泰基因自杀剂:首次获得批准

Tina Nie1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. mdt@adis.com.

Molecular diagnosis & therapy
|May 23, 2024
PubMed
概括

一种CAR T细胞疗法Talicabtagene autoleucel在复发性/耐药性B细胞恶性瘤中显示出高响应率. 这种疗法在印度获得了B细胞淋巴瘤和急性淋巴细胞白血病的批准.

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 细胞疗法细胞疗法

背景情况:

  • 复发性/耐药性B细胞恶性瘤存在重大治疗挑战.
  • 化学抗原受体 (CAR) T细胞疗法为这些血液癌症提供了一种新的方法.

研究的目的:

  • 总结一下talicabtagene autoleucel的发展里程碑.
  • 为了突出其最近对印度特定的B细胞恶性瘤的批准.

主要方法:

  • 开发talicabtagene autoleucel,一种使用与人性化的抗CD19 CAR工程自主T细胞的CAR T细胞疗法.
  • 对I期和II期临床试验数据的聚合分析.

主要成果:

  • 在患有复发性/耐药性B细胞恶性瘤的患者中,Talicabtagene自单细胞检测显示出高响应率.
  • 单次静脉注射剂在研究患者群体中是有效的.

结论:

  • 塔利卡巴特基因自杀细胞在治疗复发性/耐药性B细胞恶性瘤方面取得了重大进展.
  • 该疗法在印度获得批准,标志着该地区CAR T细胞治疗的关键里程碑.

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

488

相关实验视频

Last Updated: Jun 25, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

488